« Back
Home /
Tanshinone IIA sulfonate (sodium)

Tanshinone IIA sulfonate (sodium)

Item no.	HY-N1370-25mg
Manufacturer	MedChem Express
CASRN	69659-80-9
Amount	25 mg
Quantity options	100 mg 10 mMx1 mL 10 mg 25 mg 500 mg 50 mg 5 mg
Category	Oncology Neuroscience Molecular Targets for Neuroscience Aging & Neurological Disorders Neural Signaling Inhibitors & Compound Libraries Small Molecules By Organ Colorectal Cancer Breast Cancer
Type	Inhibitors
Specific against	other
Purity	99.77
Citations	[1]Xu QQ, et al. Sodium Tanshinone IIA Sulfonate Attenuates Scopolamine-Induced Cognitive Dysfunctions via Improving Cholinergic System. Biomed Res Int. 2016;2016:9852536\|[2]Jiang Q, et al. Sodium tanshinone IIA sulfonate inhibits hypoxia-induced enhancement of SOCE in pulmonary arterial smooth muscle cells via the PKG-PPAR-γ signaling axis. Am J Physiol Cell Physiol. 2016 Jul 1;311(1):C136-49.\|[3]Ouyang DS, et al. Kinetics of cytochrome P450 enzymes for metabolism of sodium tanshinone IIA sulfonate in vitro. Chin Med. 2016 Mar 22;11:11.\|[4]Chen D, et al. Sodium tanshinone IIA sulfonate and its interactions with human CYP450s. Xenobiotica. 2016 Dec;46(12):1085-1092. Epub 2016 Mar 2.\|[5]Lin S, et al. [Sodium tanshinone IIA sulfonate prevents postoperative peritoneal adhesions in rats by enhancing the activity of the peritoneal fibrinolytic system]. Nan Fang Yi Ke Da Xue Xue Bao. 2016 Feb;36(2):260-4.
Smiles	O=S(C1=C(C)C(C(C(C2=C3C=CC4=C2CCCC4(C)C)=O)=O)=C3O1)(O[Na])=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	Sodium Tanshinone IIA sulfonate,Tanshinone IIA sodium sulfonate
Shipping Condition	Room temperature
Available
Manufacturer - Type	Natural Products
Manufacturer - Applications	COVID-19-immunoregulation
Manufacturer - Targets	CRAC Channel
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, sealed storage, away from moisture)
Molecular Weight	396.39
Product Description	Tanshinone IIA sulfonate (sodium) is a derivative of tanshinone IIA, which acts as an inhibitor of store-operated Ca2+ entry (SOCE), and is used to treat cardiovascular disorders.
Manufacturer - Research Area	Cardiovascular Disease; Cancer
Solubility	DMSO: 62.5 mg/mL (ultrasonic)\|H2O: 2 mg/mL (ultrasonic; warming; heat to 60°C)
Manufacturer - Pathway	Membrane Transporter/Ion Channel
Clinical information	Launched

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-N1370-25mg-safety-datasheet.pdf